These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 24276029)

  • 21. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation.
    Meijers-Heijboer EJ; Verhoog LC; Brekelmans CT; Seynaeve C; Tilanus-Linthorst MM; Wagner A; Dukel L; Devilee P; van den Ouweland AM; van Geel AN; Klijn JG
    Lancet; 2000 Jun; 355(9220):2015-20. PubMed ID: 10885351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Breast cancer genetic counseling after diagnosis but before treatment: a pilot study on treatment consequences and psychological impact.
    Wevers MR; Hahn DE; Verhoef S; Bolhaar MD; Ausems MG; Aaronson NK; Bleiker EM
    Patient Educ Couns; 2012 Oct; 89(1):89-95. PubMed ID: 22543000
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized trial of a decision aid for BRCA1/BRCA2 mutation carriers: impact on measures of decision making and satisfaction.
    Schwartz MD; Valdimarsdottir HB; DeMarco TA; Peshkin BN; Lawrence W; Rispoli J; Brown K; Isaacs C; O'Neill S; Shelby R; Grumet SC; McGovern MM; Garnett S; Bremer H; Leaman S; O'Mara K; Kelleher S; Komaridis K
    Health Psychol; 2009 Jan; 28(1):11-19. PubMed ID: 19210013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRCA1/2 mutation carriers & risk reducing mastectomy: Who undergoes surgery and potential benefits.
    Record SM; Thomas SM; Ntowe K; Chiba A; Plichta JK
    Am J Surg; 2024 Jan; 227():146-152. PubMed ID: 37827871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Uptake of risk-reducing surgery in BRCA gene carriers in Wales, UK.
    Long J; Evans TG; Bailey D; Lewis MH; Gower-Thomas K; Murray A
    Breast J; 2018 Jul; 24(4):580-585. PubMed ID: 29286205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Less correspondence between expectations before and cosmetic results after risk-reducing mastectomy in women who are mutation carriers: a prospective study.
    Brandberg Y; Arver B; Johansson H; Wickman M; Sandelin K; Liljegren A
    Eur J Surg Oncol; 2012 Jan; 38(1):38-43. PubMed ID: 22032910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of preoperative BRCA1/2 testing on surgical decision making in patients with newly diagnosed breast cancer.
    Yadav S; Jinna S; Pereira-Rodrigues O; Reeves A; Campian S; Sufka A; Zakalik D
    Breast J; 2018 Jul; 24(4):541-548. PubMed ID: 29498445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
    Yamauchi H; Nakagawa C; Kobayashi M; Kobayashi Y; Mano T; Nakamura S; Arai M
    Breast Cancer; 2018 Mar; 25(2):141-150. PubMed ID: 29019095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk-reducing mastectomy decisions among women with mutations in high- and moderate- penetrance breast cancer susceptibility genes.
    Comeaux JG; Culver JO; Lee JE; Dondanville D; McArthur HL; Quinn E; Gorman N; Ricker C; Li M; Lerman C
    Mol Genet Genomic Med; 2022 Oct; 10(10):e2031. PubMed ID: 36054727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. When to Consider Risk-Reducing Mastectomy in BRCA1/BRCA2 Mutation Carriers with Advanced Stage Ovarian Cancer: a Case Study Illustrating the Genetic Counseling Challenges.
    Speight B; Tischkowitz M
    J Genet Couns; 2017 Dec; 26(6):1173-1178. PubMed ID: 28780755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
    Rebbeck TR; Friebel T; Lynch HT; Neuhausen SL; van 't Veer L; Garber JE; Evans GR; Narod SA; Isaacs C; Matloff E; Daly MB; Olopade OI; Weber BL
    J Clin Oncol; 2004 Mar; 22(6):1055-62. PubMed ID: 14981104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The frequency and outcome of breast cancer risk-reducing surgery in Finnish BRCA1 and BRCA2 mutation carriers.
    Koskenvuo L; Svarvar C; Suominen S; Aittomäki K; Jahkola T
    Scand J Surg; 2014 Mar; 103(1):34-40. PubMed ID: 24177987
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reasons for risk-reducing mastectomy versus MRI-screening in a cohort of women at high hereditary risk of breast cancer.
    Haroun I; Graham T; Poll A; Sun P; Hill K; Weitzner E; Narod S; Warner E
    Breast; 2011 Jun; 20(3):254-8. PubMed ID: 21306899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk management decisions in women with BRCA1 and BRCA2 mutations.
    Morgan R; Brown A; Hamman KJ; Sampson J; Naik A; Massimino K
    Am J Surg; 2018 May; 215(5):899-903. PubMed ID: 29499861
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers.
    Scheuer L; Kauff N; Robson M; Kelly B; Barakat R; Satagopan J; Ellis N; Hensley M; Boyd J; Borgen P; Norton L; Offit K
    J Clin Oncol; 2002 Mar; 20(5):1260-8. PubMed ID: 11870168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.
    Gamble C; Havrilesky LJ; Myers ER; Chino JP; Hollenbeck S; Plichta JK; Kelly Marcom P; Shelley Hwang E; Kauff ND; Greenup RA
    Ann Surg Oncol; 2017 Oct; 24(11):3116-3123. PubMed ID: 28699130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What made her give up her breasts: a qualitative study on decisional considerations for contralateral prophylactic mastectomy among breast cancer survivors undergoing BRCA1/2 genetic testing.
    Kwong A; Chu AT
    Asian Pac J Cancer Prev; 2012; 13(5):2241-7. PubMed ID: 22901201
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An evaluation of needs of female BRCA1 and BRCA2 carriers undergoing genetic counselling.
    Metcalfe KA; Liede A; Hoodfar E; Scott A; Foulkes WD; Narod SA
    J Med Genet; 2000 Nov; 37(11):866-74. PubMed ID: 11073541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients.
    Schwartz MD; Lerman C; Brogan B; Peshkin BN; Isaacs C; DeMarco T; Halbert CH; Pennanen M; Finch C
    Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):1003-7. PubMed ID: 15824179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.
    Friebel TM; Domchek SM; Neuhausen SL; Wagner T; Evans DG; Isaacs C; Garber JE; Daly MB; Eeles R; Matloff E; Tomlinson G; Lynch HT; Tung N; Blum JL; Weitzel J; Rubinstein WS; Ganz PA; Couch F; Rebbeck TR
    Clin Breast Cancer; 2007 Dec; 7(11):875-82. PubMed ID: 18269778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.